It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

pharmaceuticals

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Testing times: More work needed on AstraZeneca/Oxford vaccine trials

World / Science & Health Dec 9, 2020

Testing times: More work needed on AstraZeneca/Oxford vaccine trials

by Kate Kelland

A Lancet study gave few extra clues about why efficacy was 62% for trial participants given two full doses, but 90% for a smaller subgroup given a half, then a full dose.

After admitting error, AstraZeneca faces hard questions on vaccine

World / Science & Health Nov 26, 2020

After admitting error, AstraZeneca faces hard questions on vaccine

by Rebecca Robbins and Benjamin Mueller

Scientists said a series of irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results.

Not so fast, Japan experts say, as COVID-19 vaccines raise hopes

National / Science & Health Nov 25, 2020

Not so fast, Japan experts say, as COVID-19 vaccines raise hopes

by Osamu Tsukimori

Medical experts say long-term safety and efficacy concerns remain as the vaccines are developed in record-setting time.

Decades of work, and half a dose of fortune, drove Oxford vaccine success

World / Science & Health | FOCUS Nov 24, 2020

Decades of work, and half a dose of fortune, drove Oxford vaccine success

by Alistair Smout, Kate Kelland and Ludwig Burger

The Oxford vaccinologists were exhilarated on Monday when drugmaker AstraZeneca, with whom they developed the shot, announced that it could be around 90% effective.

Two companies say their vaccines are 95% effective. What does that mean?

World / Science & Health Nov 21, 2020

Two companies say their vaccines are 95% effective. What does that mean?

by Carl Zimmer

You might assume that 95 out of every 100 people vaccinated will be protected from COVID-19. But that’s not how the math works.

WHO advises doctors not to use Gilead’s remdesivir for COVID-19

World / Science & Health Nov 20, 2020

WHO advises doctors not to use Gilead’s remdesivir for COVID-19

The recommendation is a blow to Gilead’s drug, which was one of the first thought to offer a meaningful benefit in treatment of coronavirus patients.

Can first vaccines bring herd immunity? Experts have doubts.

World / Science & Health Nov 19, 2020

Can first vaccines bring herd immunity? Experts have doubts.

by Ludwig Burger and Kate Kelland

Figuring out what's needed to achieve herd immunity with COVID-19 vaccines involves a range of factors, several of which are unknown.

China takes risk in rushing to use unproven coronavirus vaccines

Asia Pacific / Science & Health Nov 18, 2020

China takes risk in rushing to use unproven coronavirus vaccines

by Sui-lee Wee and Elsie Chen

China has made its unproven candidates widely available to demonstrate their safety and effectiveness to a country that has long been skeptical of vaccines.

Sinovac's COVID-19 vaccine induces quick immune response, study finds

Asia Pacific / Science & Health Nov 18, 2020

Sinovac's COVID-19 vaccine induces quick immune response, study finds

Sinovac Biotech's experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday. While the early to mid-stage trials were not designed to assess ...

Pfizer reaches safety milestone for COVID-19 vaccine, CEO says

World / Science & Health Nov 18, 2020

Pfizer reaches safety milestone for COVID-19 vaccine, CEO says

Pfizer Inc. Chief Executive Officer Albert Bourla said that a key safety milestone had been reached in the study of its COVID-19 vaccine, and the drugmaker is now preparing to seek an emergency-use authorization from U.S. regulators. Speaking at a virtual conference hosted by The ...

How Pfizer and BioNTech sprinted ahead in extraordinary race for a COVID-19 vaccine

World / Science & Health | FOCUS Nov 18, 2020

How Pfizer and BioNTech sprinted ahead in extraordinary race for a COVID-19 vaccine

by Michael Erman and Julie Steenhuysen

Researchers were asked to tackle something that had never been done before: design a vaccine to stop a pandemic in its tracks in less than a year.

Moderna’s COVID-19 vaccine: What you need to know

World / Science & Health Nov 17, 2020

Moderna’s COVID-19 vaccine: What you need to know

by Carl Zimmer

Coming a week after similar news from Pfizer and BioNTech, Moderna's announcement offered more hope that there’s going to be a way out of the pandemic.

« 1 … 25 26 27 … 42 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times